Introducing Crowell & Moring’s Compliance “Check-Up” for Government Contractors
Client Alert | 1 min read | 03.06.18
The Government Contracts and Corporate Groups at Crowell & Moring LLP are pleased to announce our Compliance “Check-Up” for Government Contractors, focused on providing pre-sale advice to government contractors and private equity sponsors contemplating selling or fundraising in the current market. Our team of over 80 experienced government contracts and transactional professionals stands ready to assist clients by providing (at no cost) a “Check-Up” – a diagnostic review of key diligence questions, aimed at identifying common compliance issues that can drive down sales prices and/or increase borrowing costs. By identifying these issues early in the diligence process, sellers can avoid common traps that may negatively impact deal terms, complicate reps and warranties, and make post-merger integration more difficult and expensive. For more information on our Compliance “Check-Up” for Government Contractors, please click here.
Contacts
Partner
She/Her/Hers
Insights
Client Alert | 4 min read | 04.10.25
Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”
In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
Client Alert | 1 min read | 04.09.25
Client Alert | 12 min read | 04.09.25
Client Alert | 4 min read | 04.07.25
